|
US9242976B2
(en)
*
|
2012-01-13 |
2016-01-26 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
WO2013106612A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
EP2903617B1
(en)
*
|
2012-10-08 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
PE20150953A1
(es)
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
|
|
ES2616812T3
(es)
|
2012-11-08 |
2017-06-14 |
Bristol-Myers Squibb Company |
Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CA2985542C
(en)
|
2015-05-20 |
2023-10-10 |
Amgen Inc. |
Triazole agonists of the apj receptor
|
|
AR105113A1
(es)
*
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
|
UY36747A
(es)
*
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
|
US10618903B2
(en)
|
2015-06-24 |
2020-04-14 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
WO2017192485A1
(en)
|
2016-05-03 |
2017-11-09 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the apj receptor
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
CN115448916A
(zh)
*
|
2016-10-14 |
2022-12-09 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
WO2018093579A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the apj receptor
|
|
US11020395B2
(en)
|
2016-11-16 |
2021-06-01 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
|
|
US11191762B2
(en)
|
2016-11-16 |
2021-12-07 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the APJ Receptor
|
|
WO2018097944A1
(en)
|
2016-11-16 |
2018-05-31 |
Amgen Inc. |
Triazole furan compounds as agonists of the apj receptor
|
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
|
EP3541805B1
(en)
|
2016-11-16 |
2020-10-14 |
Amgen Inc. |
Heteroaryl-substituted triazoles as apj receptor agonists
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
MY200228A
(en)
|
2017-05-11 |
2023-12-15 |
Bristol Myers Squibb Co |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
MA50509A
(fr)
|
2017-11-03 |
2021-06-02 |
Amgen Inc |
Agonistes de triazole fusionnés du récepteur apj
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
MX2020006587A
(es)
|
2017-12-22 |
2020-12-10 |
Ravenna Pharmaceuticals Inc |
Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CN110317190A
(zh)
*
|
2018-03-28 |
2019-10-11 |
首都医科大学 |
一种三唑-羧酸酯类衍生物在医药领域的应用
|
|
MA52487A
(fr)
|
2018-05-01 |
2021-03-10 |
Amgen Inc |
Pyrimidinones substituées en tant qu'agonistes du récepteur apj
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
MX2021015995A
(es)
|
2019-06-28 |
2022-03-11 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021011727A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
CN114174279B
(zh)
|
2019-08-06 |
2024-07-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂环化合物
|
|
US12570659B2
(en)
|
2019-08-13 |
2026-03-10 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN115052627A
(zh)
|
2019-12-17 |
2022-09-13 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
CN115335380B
(zh)
|
2020-02-03 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的三环杂芳基化合物
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
KR20230084145A
(ko)
*
|
2020-09-30 |
2023-06-12 |
아사히 가세이 파마 가부시키가이샤 |
피리미딘 함유 함질소 2환 화합물
|
|
CA3202360A1
(en)
|
2020-12-30 |
2022-07-07 |
Nello Mainolfi |
Irak degraders and uses thereof
|
|
CA3207049A1
(en)
|
2021-02-15 |
2022-08-18 |
Jared Gollob |
Irak4 degraders and uses thereof
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2026005537A1
(ko)
*
|
2024-06-28 |
2026-01-02 |
주식회사 대웅제약 |
신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물
|